• Search
  • Advanced Search

Review

February 28, 2024


Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis
Jiaorong Qu, Le Wang, Yufei Li, et al.
Clin Mol Hepatol. 2024;30(3):303-325.

Liver sinusoidal endothelial cells (LSECs) are liver-specific endothelial cells with the highest permeability than other mammalian endothelial cells, characterized by the presence of fenestrae on their surface, the absence of...

Review

April 26, 2024


Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, et al.
Clin Mol Hepatol. 2024;30(3):326-344.
Hepatitis C virus (HCV) infection is one of the major etiologies of hepatocellular carcinoma (HCC) with approximately 30% of HCC being due to HCV infection worldwide. HCV eradication by antivirals...

Original Article

March 12, 2024


Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Young Eun Chon, Dong Yun Kim, Mi Na Kim, et al.
Clin Mol Hepatol. 2024;30(3):345-359.

Background/Aims: Atezolizumab plus bevacizumab (ATE+BEV) therapy has become the recommended first-line therapy for patients with unresectable hepatocellular carcinoma (HCC) because of favorable treatment responses. However, there is a lack of...

Original Article

March 15, 2024


Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma
Jiwon Hong, Jung Woo Eun, Geum Ok Baek, et al.
Clin Mol Hepatol. 2024;30(3):360-374.

Background/Aims: Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide. Despite identification of several biomarkers for HCC diagnosis, challenges such as low sensitivity and intratumoral heterogeneity have impeded...

Original Article

March 26, 2024


Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, et al.
Clin Mol Hepatol. 2024;30(3):375-387.

Background/Aims: Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells....

Original Article

April 11, 2024


Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment
Do Seon Song, Hee Yeon Kim, Young Kul Jung, et al.
Clin Mol Hepatol. 2024;30(3):388-405.

Background/Aims: Quick sequential organ failure assessment (qSOFA) is believed to identify patients at risk of poor outcomes in those with suspected infection. We aimed to evaluate the ability of modified...

Original Article

April 11, 2024


Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma
Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, et al.
Clin Mol Hepatol. 2024;30(3):406-420.

Background/Aims: The performance of machine learning (ML) in predicting the outcomes of patients with hepatocellular carcinoma (HCC) remains uncertain. We aimed to develop risk scores using conventional methods and ML...

Original Article

April 11, 2024


Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver grafts
Shuai Wang, Xiaohong Lin, Yunhua Tang, et al.
Clin Mol Hepatol. 2024;30(3):421-435.

Background/Aims: The shortage of donor liver hinders the development of liver transplantation. This study aimed to clarify the poor outcomes of functionally marginal liver grafts (FMLs) and provide evidence for...

Original Article

April 16, 2024


Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
Harry Crane, Guy D. Eslick, Cameron Gofton, et al.
Clin Mol Hepatol. 2024;30(3):436-448.

Background/Aims: The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis...

Original Article

April 16, 2024


Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease
Yiyuan Zheng, Lina Zhao, Zhekun Xiong, et al.
Clin Mol Hepatol. 2024;30(3):449-467.

Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) has become an increasingly important health challenge, with a substantial rise linked to changing lifestyles and global obesity. Ursolic acid, a natural pentacyclic...

Original Article

April 19, 2024


Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy
Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Clin Mol Hepatol. 2024;30(3):468-486.

Background/Aims: Chronic hepatitis C (CHC) patients who failed antiviral therapy are at increased risk for hepatocellular carcinoma (HCC). This study assessed the potential role of metformin and statins, medications for...

Original Article

May 7, 2024


Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, et al.
Clin Mol Hepatol. 2024;30(3):487-499.

Background/Aims: To determine the association between evolutionary changes in metabolic dysfunction-associated steatotic liver disease (MASLD) status and the risk of hepatocellular carcinoma (HCC) in a nationwide population-based cohort. Methods: Information on...

Original Article

May 10, 2024


Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, et al.
Clin Mol Hepatol. 2024;30(3):500-514.

Background/Aims: Chronic hepatitis B (CHB) is related to an increased risk of extrahepatic malignancy (EHM), and antiviral treatment is associated with an incidence of EHM comparable to controls. We compared...

Original Article

May 10, 2024


Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy
Qi Wang, Qingfa Bu, Zibo Xu, et al.
Clin Mol Hepatol. 2024;30(3):515-538.

Background/Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is an unmet clinical challenge due to the rapid increased occurrence but lacking approved drugs. Autophagy-related protein 16-like 1 (ATG16L1) plays an important role in...

Original Article

May 14, 2024


Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction
Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, et al.
Clin Mol Hepatol. 2024;30(3):539-560.

Background/Aims: The major histocompatibility class II (MHC II) transactivator, known as CIITA, is induced by Interferon gamma (IFN-γ) and plays a well-established role in regulating the expression of class II...

Original Article

June 3, 2024


Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis
Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, et al.
Clin Mol Hepatol. 2024;30(3):561-576.

Background/Aims: Bariatric intervention has been reported to be an effective way to improve metabolic dysfunction-associated steatotic liver disease (MASLD) in obese individuals. The current systemic review aimed to assess the...
Current Issue
Volume 30(3); Jul 2024
Review
1896
Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis
Jiaorong Qu, Le Wang, Yufei Li, Xiaojiaoyang Li
Clin Mol Hepatol. 2024;30(3):303-325.   Published online February 28, 2024
View: 2963   Download: 250  Web of Science: 1  Crossref: 2
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(3):326-344.   Published online April 26, 2024
View: 1978   Download: 135  Crossref: 1
Original Article
1904
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol. 2024;30(3):345-359.   Published online March 12, 2024
View: 2972   Download: 349  Web of Science: 1  Crossref: 3
1905
Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma
Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim
Clin Mol Hepatol. 2024;30(3):360-374.   Published online March 15, 2024
View: 2994   Download: 267  Web of Science: 1  Crossref: 3
1908
Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery
Clin Mol Hepatol. 2024;30(3):375-387.   Published online March 26, 2024
View: 2083   Download: 94  Crossref: 1
1912
Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment
Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Yang, Dong Joon Kim, Ashok Kumar Choudhury, Vinod Arora, Shiv Kumar Sarin
Clin Mol Hepatol. 2024;30(3):388-405.   Published online April 11, 2024
View: 2054   Download: 82
1913
Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma
Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, Chi-Jen Chu, Yi-Hsiang Huang, Teh-Ia Huo, Yu-Hui Su, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
Clin Mol Hepatol. 2024;30(3):406-420.   Published online April 11, 2024
View: 2308   Download: 136  Crossref: 2
1914
Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver grafts
Shuai Wang, Xiaohong Lin, Yunhua Tang, Yichen Liang, Min Zhang, Zhonghao Xie, Yiwen Guo, Yuqi Dong, Qiang Zhao, Zhiyong Guo, Dongping Wang, Xiaoshun He, Weiqiang Ju, Maogen Chen
Clin Mol Hepatol. 2024;30(3):421-435.   Published online April 11, 2024
View: 1884   Download: 124
1918
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George
Clin Mol Hepatol. 2024;30(3):436-448.   Published online April 16, 2024
View: 2775   Download: 231  Crossref: 3
1917
Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease
Yiyuan Zheng, Lina Zhao, Zhekun Xiong, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Yugang Fu, Simin Gu, Chong Chen, Jiacheng Li, Yingying Zhu, Jing Liu, Fengbin Liu, Yong Li
Clin Mol Hepatol. 2024;30(3):449-467.   Published online April 16, 2024
View: 2879   Download: 319
1919
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy
Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Hsing-Tao Kuo, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Cheng-Yuan Peng, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Jia-Horng Kao, Chun-Jen Liu, Chen-Hua Liu, Sheng-Lei Yan, Chun-Yen Lin, Wei-Wen Su, Cheng-Hsin Chu, Chih-Jen Chen, Shui-Yi Tung, Chi‐Ming Tai, Chih-Wen Lin, Ching-Chu Lo, Pin-Nan Cheng, Yen-Cheng Chiu, Chia-Chi Wang, Jin-Shiung Cheng, Wei-Lun Tsai, Han-Chieh Lin, Yi-Hsiang Huang, Chi-Yi Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chung, Ming-Jong Bair, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(3):468-486.   Published online April 19, 2024
View: 2402   Download: 151
1926
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park
Clin Mol Hepatol. 2024;30(3):487-499.   Published online May 7, 2024
View: 1981   Download: 174
1927
Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon
Clin Mol Hepatol. 2024;30(3):500-514.   Published online May 10, 2024
View: 1876   Download: 144
1928
Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy
Qi Wang, Qingfa Bu, Zibo Xu, Yuan Liang, Jinren Zhou, Yufeng Pan, Haoming Zhou, Ling Lu
Clin Mol Hepatol. 2024;30(3):515-538.   Published online May 10, 2024
View: 2335   Download: 226
1931
Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction
Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim
Clin Mol Hepatol. 2024;30(3):539-560.   Published online May 14, 2024
View: 2225   Download: 221
1942
Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis
Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, Bo Hyun Kim, Seong Hee Kang, Jeong-Ju Yoo, Mi Young Choi, Dong eun Lee, Dae Won Jun, Yuri Cho
Clin Mol Hepatol. 2024;30(3):561-576.   Published online June 3, 2024
View: 1888   Download: 117  Web of Science: 1  Crossref: 1
Letter to the Editor
1902
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Clin Mol Hepatol. 2024;30(3):577-579.   Published online March 6, 2024
View: 1758   Download: 135  Web of Science: 3  Crossref: 2
Functional cure of chronic hepatitis B encounters resmetirom
Nai-Bin Yang, Wai-Kay Seto, Ming-Hua Zheng
Clin Mol Hepatol. 2024;30(3):580-581.   Published online April 30, 2024
View: 1509   Download: 87
Snapshot
1874
Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen
Clin Mol Hepatol. 2024;30(3):582-584.   Published online December 29, 2023
View: 6524   Download: 81

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS
FOLLOW US
Twitter
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 491
TOTAL : 2057338
Close layer